CTIS2022-501342-29-00招募中1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma - MK 7902-014
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 808
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Has a histologically or cytologically confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus, Male participants are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or 90 days after the last dose of chemotherapy, whichever comes last; 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only and is greater than 90 days post chemotherapy, no male contraception is needed, Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP using a contraceptive method that is highly effective or is abstinent from heterosexual intercourse as their preferred and usual lifestyle during the intervention period and for at least 120 days after the last dose of pembrolizumab, 30 days after the last dose of lenvatinib, or 180 days after the last dose of chemotherapy, whichever occurs last, and agrees not to donate eggs during this period, Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP=150/90 millimeters of mercury (mm Hg) with no change in antihypertensive medications within 1 week prior to randomization, Has adequate organ function
排除标准
- •Has had previous therapy for locally advanced unresectable or metastatic esophageal cancer, Has had major surgery, open biopsy, or significant traumatic injury within 3 weeks prior to first dose of study interventions, Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis, Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed, Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, or has a history of organ transplant, including allogeneic stem cell transplant, Has a known additional malignancy that is progressing or has required active treatment within the past 3 years, Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis, Has an active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed, Has a history of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease, Has poorly controlled diarrhea, Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, Has locally advanced esophageal carcinoma, Has peripheral neuropathy =Grade 2, Has a known history of human immunodeficiency virus (HIV) infection, Has a known history of Hepatitis B or know active Hepatitis C virus infection, Has a weight loss of >20% within the last 3 months, Has metastatic adenocarcinoma of the esophagus, Has direct invasion into adjacent organs such as the aorta or trachea, Has radiographic evidence of encasement of a major blood vessel, or of intratumoral cavitation, Has perforation risks or significant gastrointestinal (GI) bleeding, Has had clinically significant hemoptysis within 3 weeks prior to the first dose of study drug or tumor bleeding within 2 weeks prior to the first dose of study intervention, Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention, Has GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent
研究者
相似试验
进行中（未招募）
1 期
A Study to Compare the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Myelofibrosis who were Treated with RuxolitinibPrimary Myelofibrosis, Post-polycythemia Vera Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.MedDRA version: 18.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-005007-13-FRGilead Sciences Inc.150
进行中（未招募）
1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal CarcinomaEUCTR2020-001911-26-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.862
进行中（未招募）
1 期
A Study to Compare the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Myelofibrosis who were Treated with RuxolitinibEUCTR2013-005007-13-GBSierra Oncology, Inc.150
进行中（未招募）
3 期
Pembrolizumab plus Lenvatinib plus Chemotherapy for the Treatment of Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction AdenocarcinomaJPRN-jRCT2051200127Koh Yasuhiro120
进行中（未招募）
1 期
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)EUCTR2020-001990-53-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.790